

1 **Protective microbiomes can limit the evolution of host pathogen defense**

2

3 C. Jessica E. Metcalf^{1,*}, Britt Koskella²

4

5 ¹Department of Ecology and Evolutionary, Princeton University, Princeton, NJ, USA

6 ²Department of Integrative Biology, UC Berkeley, Berkeley, CA, USA

7

8 *Author for correspondence: cmetcalf@princeton.edu

9

10 *keywords:* immunity, immune discrimination, protective symbionts, pathobiome, host evolution

11

12 **Abstract**

13 The evolution of host immunity occurs in the context of the microbiome, but little theory exists to
14 predict how resistance against pathogens might be influenced by the need to tolerate and
15 regulate commensal microbiota. We present a general model to explore the optimal investment in
16 host immunity under conditions in which the host can, versus cannot easily distinguish among
17 commensal versus pathogenic bacteria; and when commensal microbiota can, versus cannot
18 protect the host against the impacts of pathogen infection. We find that a loss of immune
19 vigilance associated with innate immunity over evolutionary time can occur due to the challenge
20 of discriminating between pathogenic and other microbe species. Further, we find the greater the
21 protective effect of microbiome species, acting either directly or via competition with a pathogen,
22 or the higher the costs of immunity, the more likely the loss of immune vigilance is. Conversely,
23 this effect can be reversed when pathogens increase host mortality. Generally, the magnitude of
24 costs of immunity required to allow evolution of decreased immune vigilance are predicted to be
25 lowest when microbiome and pathogen species most resemble each other (in terms of host
26 recognition), and when immune effects on the pathogen are weak. Our model framework makes
27 explicit the core trade-offs likely to shape the evolution of immunity in the context of microbiome /
28 pathogen discrimination. We discuss how this informs interpretation of patterns and process in
29 natural systems, including vulnerability to pathogen emergence.

30

31 **Impact Summary**

32 Evidence for impacts of the microbiome on host health is accumulating. Despite this, little theory
33 has been developed to delineate the evolutionary trajectories that might lead to observed host-
34 microbiome associations. One particularly important theoretical gap is evaluating how the
35 presence and effects of microbiome species modify selection pressure on immune system
36 function. We develop a simple model of host fitness given both immune discrimination and
37 microbiome and pathogen effects on survival, in the context of an interaction between the
38 microbiome and pathogen species. We use this framework to predict when and to what degree
39 the presence of microbiome species might lead to loss of immune vigilance. Positive microbiome
40 effects can drive loss of immune vigilance, whether the microbiome acts directly on pathogen
41 growth or indirectly by reducing the impacts of pathogens; and high costs of immunity will amplify
42 this effect. Our results provide a first set of predictions regarding how immunity should evolve
43 given the challenge of discriminating pathogen and microbiome species, and reveals the ways in
44 which this might leave hosts vulnerable to novel pathogens.

45

46 **Introduction**

47 Bacterial species making up the microbiome are increasingly recognized to play an important role
48 in host health, including via microbiome-mediated protection against pathogens (Friesen et al.
49 2011). An important implication is that the evolution of host immunity must have occurred in the
50 context of balancing tolerance of commensals and resisting pathogens (Littman and Pamer
51 2011). As a result, underlying ecological features of both hosts and bacteria will define how
52 selection shapes host immunity across host generations. For example, microbiome-mediated
53 protection might evolve very rapidly, due to both shorter microbial generation times and greater
54 standing genetic variation. The resulting protection against pathogens enjoyed by the host might
55 hinder the evolution of host genetic resistance (King and Bonsall 2017). Growing evidence also
56 suggests that the microbiome plays a critical role in shaping the breadth and specificity of host
57 immunity (Thaiss et al. 2016). This will also shape selection pressures on host immunity to resist
58 pathogens. Despite increasing recognition of the importance of the microbiome in host ecology
59 and health, mathematical models of core processes remains rare, and there is little theory to
60 guide expectations (Koskella, Hall, and Metcalf 2017).

61

62 To adequately reflect natural systems of interest, mathematical models must capture several
63 interlocking aspects of the ecology and co-evolution underpinning microbiome-mediated
64 protection. Here, we focus our investigation on innate immunity, the first line of defense against
65 pathogens, found across species from plants to vertebrates. We ask how the presence of
66 commensal microbiota might shape selection on how hosts trigger innate immunity. Innate
67 immunity would ideally be launched when molecular signatures of pathogens were detected.
68 Since pathogens will rapidly evolve away from any signature that is detectable by innate
69 immunity, and that is not subject to constraints, typically, the molecular signatures used by innate
70 immunity are highly conserved among bacteria. The bacterial flagellin protein is a classic
71 example (Gómez-Gómez and Boller 2002) - this apparently tightly constrained structure is widely
72 used by hosts as a strong trigger of host innate immunity (Felix et al. 1999). Importantly, the
73 result is that pathogens and commensal microbiota are likely to have overlapping expression of
74 molecules used by the host in detection of pathogens (Levy et al. 2018; Vogel et al. 2016). The
75 decision to trigger an immune response must therefore discriminate between the presence of
76 pathogens and (neutral or even beneficial) microbiota despite these similarities. Hosts are left
77 with a fundamental tension between maintaining a diverse microbiome and defending against
78 pathogens despite these similarities. This tension remains poorly understood.

79

80 The problem is further complicated by the ability of many commensal microbiota to play a role in
81 host defense by either excluding pathogen colonization and growth, or reducing the impact of
82 pathogens on host health (Snelders et al. 2018). This might (or might not) echo molecular
83 signatures underlying detection by immunity, for example if phylogenetically related pathogenic
84 and commensal bacteria were more likely to compete for shared resources and were recognized
85 by the immune system through shared mechanisms. In this case, reducing immune vigilance may
86 allow for the proliferation of particular commensal microbiota that directly compete with invading
87 pathogens, reducing the need for hosts to invest in immunity (Hrček et al. 2018; Jaenike 2012).
88 Many lines of evidence suggest that triggering an immune reaction is likely to be costly (Hanssen

89 et al. 2004; Sheldon and Verhulst 1996) and thus walking the line between effective pathogen
90 defenses and regulating microbiome homeostasis should be a ubiquitous but non-trivial
91 challenge.

92
93 Here, we ask how host innate immunity might evolve in the presence of a commensal microbiota
94 with the potential to diminish pathogen impact on the host via competition. Since many molecules
95 used by hosts to trigger innate immunity are evolutionarily constrained (e.g., flagellin (Gómez-
96 Gómez and Boller 2002)), we initially assume that evolution in pathogen and commensal
97 microbiota communities is negligible. We capture the impacts of pathogen and commensal
98 microbiota on fitness through a simple mapping from their abundance to host survival (rather than
99 developing a complete dynamical description of the interactions between pathogens, commensal
100 microbiota and host immunity; e.g., as in (Leung and Weitz 2019)). To capture the discrimination
101 problem faced by innate immunity, we assume that pathogens and commensal microbiota can be
102 reflected as being distribution along a single axis, representing a range from a 'small' to a 'large'
103 signal detectable by the immune system, which might reflect aspects such as the number of CpG
104 repeats (detectable by Toll-like-receptor 9 (Pohar et al. 2015)), immunogenically variable aspects
105 of flagellin (Felix et al. 1999; Trdá et al. 2014), or a combined signal integrating presence of
106 highly conserved microbe-associated molecules with functional characteristics indicative of
107 pathogen's presence (e.g., via NBS-LRR proteins in plants (DeYoung and Innes 2006) and
108 signatures of 'stress' or deviation from homeostasis more broadly (Chovatiya and Medzhitov
109 2014)). From this, we develop a model framework constructed around core principles from
110 epidemiology to better understand the drivers of the evolution of host defense in the context of
111 pathogen-microbiome interactions. We aim in particular to delineate the conditions under which
112 the presence of commensal microbiota may result in loss of immune vigilance altogether. Our
113 results show that loss of vigilance driven by protective microbiota is possible, and its likelihood
114 increases as similarity between the commensal microbiota and pathogen communities increases,
115 and when immune effectiveness against the pathogen is weak. We discuss how evolution by
116 pathogen and commensal microbiota communities might modulate outcomes for the host, and
117 how these consequences might play out across host life histories.

118

119 **Methods and Results**

120

121 *A discrimination trade-off*

122 The problem faced by the immune system in discriminating between 'good' commensals and
123 'bad' pathogens is analogous to a classic challenge from epidemiology. Overlap between two
124 categories along a continuum means that choosing where to draw a line to discriminate between
125 them results in a trade-off between falsely allocating individuals to one or the other category
126 (Figure 1). In this example, the two distributions correspond to the community of commensal
127 microbiota (left) and pathogenic microbiota (right); the height of the two distributions reflects the
128 number of individuals in each category corresponding to each value along the continuum (e.g.
129 shared flagellin characteristics). The immune strategy under selection corresponds to the
130 problem of where to draw the line above which an immune reaction is triggered. If we define the
131 commensal microbiota as the community of microbial species with positive effects, ideally, the
132 line would have all individuals from this community to its left, where no immune response is

133 triggered, and all pathogenic microbiota to its right, where immunity acts to clear microbial
134 species. However, the predicted overlap between these two communities means that this would
135 be impossible. Drawing the line to the far left of the plot corresponds to a strategy of ‘total
136 vigilance,’ where every single microbe along the continuum triggers a reaction (with associated
137 costs of immune response). We refer to this as “100% vigilance”. Drawing the line to the far right
138 of the plot corresponds to a strategy of ‘no vigilance’, where no microbe elicits an immune
139 reaction. If there is overlap between the two distributions, drawing the line towards the middle of
140 the plot (e.g., the intermediate strategy illustrated in Figure 1) inevitably mis-classifies some
141 individuals: some members of the commensal microbiota will be above the line, and some
142 members of the pathogenic microbiota below it. The strategy that maximizes fitness will balance
143 costs of immunity with costs and benefits of pathogens and commensal microbiota, and the effect
144 of their overlap, i.e., the impact of the commensal microbiota on the pathogen relative to
145 outcomes for the host.

146
147 This framing reduces the effects of immune discrimination and competition between commensal
148 and pathogenic bacteria to being organized along a single dimension (the x axis on Figure 1);
149 and furthermore assumes that all microbial species classified as ‘commensal’ and all those
150 classified as ‘pathogenic’ have identical effects on host fitness. Both these features are
151 simplifications. If, for example, the beneficial effect of commensal species is highest for those
152 species that most resemble the pathogenic species, this will considerably alter the optimal
153 threshold for an immune response, as it will no longer make sense to sacrifice some of these
154 beneficial species to control the pathogenic species. Nevertheless, it provides a starting point for
155 framing the challenges faced by immunity, and might be appropriate if variation along the scale of
156 discrimination available to the immune system (x axis on Figure 1) overwhelms the individual
157 species differences in terms of effects on the host within the categories commensal and
158 pathogenic microbiota.

159
160 *Defining survival probability in the context of a discrimination trade-off*

161 To move from our conceptual mapping of the challenge faced by the immune system (Figure 1)
162 to a measure of host fitness, we express host survival as the outcome of mortality hazards
163 associated with each context. We can express the hazard of mortality for an individual as:

164
165
$$\mu = \mu_b + A\mu_d + B\mu_dc + C\mu_dr_p + D\mu_dr_pc + E\mu_m + F\mu_mr_m + (C + D + F)I \quad [1]$$

166
167 where the quantities A , B , C , D , E , and F refer to areas as shown on Figure 1 ($A+B+C+D$
168 captures the areas occupied by the pathogenic microbiota, and $E+F$ areas occupied by the
169 commensal microbiota); μ_b is a baseline mortality hazard, μ_d is the mortality hazard associated
170 with the presence of the pathogenic species (and corresponds to their ‘virulence’), μ_m is the
171 mortality hazard associated with the presence of the commensal microbiota (and is either zero or
172 negative). The parameter r_p captures the host’s resistance to the pathogenic microbiota, e.g., its
173 ability to reduce the mortality hazard associated with the presence of pathogenic species to the
174 right of the immune threshold line. This parameter is contained between 0 and 1, where $r_p = 1$
175 indicates no effect of the host on the pathogenic species’ impact, and $r_p = 0$ indicates that the
176 host completely eliminates the effects of the pathogenic species. For completeness, r_m captures

177 how much the host reduces the effect of the commensal microbiota. Where the microbiome has
178 beneficial effects on survival ($\mu_m < 0$) this will translate into the host tolerating their commensal
179 microbiota if $r_p = 1$, and eliminating the beneficial effects if $r_p = 0$. The parameter c captures the
180 degree to which the presence of the commensal microbiota reduces the mortality hazard by the
181 pathogenic microbiota (e.g., by outcompeting or interfering with them) in a manner dependent on
182 their overlap along the continuous axis used by the host. This parameter c is also contained
183 between 0 and 1, with larger values indicating less effective competition by the microbiome. The
184 parameter I captures the cost of an immune response, and is multiplied by all contexts where an
185 immune reaction has been triggered (e.g., area to the right of the vertical line, shaded yellow,
186 Figure 1).

187
188 To evaluate the outcome of different scenarios for the host, each mortality hazard must be
189 multiplied by the relevant area reflecting the combination of the distribution of commensal and
190 pathogenic microbiota, and the positioning of the immune threshold, as labelled on Figure 1; with
191 A, the area below the threshold for immunity consisting of only the pathogen; B the area below
192 the threshold where the pathogenic microbiota overlaps with the commensal microbiota; C, the
193 area above the threshold where only the pathogenic microbiota is present; D, the area above the
194 threshold where both pathogenic and commensal microbiota are present (Figure 1); E, the area
195 where the commensal microbiota is below the threshold; and F, the area where the commensal
196 microbiota is above the threshold and thus potentially eliciting an immune response. An
197 individual's probability of survival, as a function of the presence of the pathogen and its immune
198 threshold can then be expressed by $s = \exp(-\mu)$.

199
200 *Selection on the immune threshold*

201 Assuming that fertility is not affected by either the microbiota or the immune strategy adopted by
202 the host, maximising survival will maximize host fitness. We can evaluate evolutionary outcomes
203 schematically, mapping out how different contributions to the hazard change as the threshold
204 moves from left (complete immune vigilance) to right (no immune vigilance), and from this,
205 characterize how increases in each of the contributions to the mortality hazard modulates the
206 optimal immune threshold, which is defined by the strategy corresponding to the lowest summed
207 hazard and thus highest survival (Figure 2). This indicates that high costs of immunity, or positive
208 effects of the microbiome could shift the optimal towards 'no vigilance' (i.e., drive hosts towards
209 the evolution of no immunity). Indirect effects of the commensal microbiota on pathogen growth,
210 for example, whereby commensal microbiota competition reduces pathogen hazard, could also
211 have this effect.

212
213 Using basic probability, we can calculate the areas A-F. For simplicity, we can first evaluate
214 outcomes where the two distributions are perfectly overlapping. This also captures the scenario
215 where the pathogenic microbiota has evolved to be indistinguishable from the commensal
216 microbiota. In this situation, $A = C = 0$; $B = E$ and $D = F = 1 - B$. The equation becomes:

217
218
$$\mu = \mu_b + B[\mu_m(1 - r_m) + \mu_d c(1 - r_p) - 2I] + \mu_m r_m + \mu_d r_p c + 2I \quad [2]$$

219

220 As the immune threshold moves from left to right, reflecting a transition from complete vigilance
221 by the immune system to no vigilance at all, the magnitude of the area denoted B increases
222 (Figure 1). As a result, the sign of the factor multiplying B will determine whether the outcome of
223 evolution in the presence of a commensal microbiota is effectively the absence of an immune
224 response or a complete immune response (we expect purely binary outcomes in this simple
225 scenario). From this, selection for no vigilance requires that:

226

$$227 \quad 0.5[\mu_m(1 - r_m) + \mu_d c(1 - r_p)] > I \quad [3]$$

228

229 This relationship indicates that the cost of immunity (I) required to drive evolution in the host
230 towards a strategy of no immune vigilance will increase: (i) as the hazards increase (whether
231 associated with the commensal microbiota or the pathogenic microbiota); (ii) when the effect of
232 competition from the commensal microbiota on the pathogenic microbiota is reduced (reflected by
233 increased values of c); or (iii) if the impact of immunity on the hazards is increased (reflected by
234 decreased values of either r_m or r_p).

235

236 Focusing on the magnitude of immune cost (I) required to drive complete loss of immune
237 vigilance provides a tractable focus for understanding life history constraints (given the array of
238 potential parameters), as well as being of biological interest. Extending results presented in eqn
239 [3] numerically (Figure 3A), we can plot the magnitude of the cost of immunity (I) required for
240 evolution to the point of no immune vigilance across a spectrum of commensal and pathogenic
241 microbiota-mediated hazards, and across a range of overlaps between commensal and
242 pathogenic microbiota (Figure 3B, x axis). The required immune cost associated with loss of all
243 immune vigilance increases as overlap declines (Figure 3B, y axis), with higher costs required for
244 lower pathogen hazards (Figure 3B, colours), or in the presence of a commensal microbiota
245 (Figure 3B, line types); and costs decline with diminishingly effective pathogen immunity r_p
246 (Figure 3B, left to right panels).

247

248 How will competition shape the evolution of immune vigilance? To explore this, we can evaluate
249 survival at a range of immune thresholds in the absence ($c = 1$, Figure 4, left) versus presence
250 ($c = 0$, Figure 4, right) of competition across a spectrum of pathogenic microbiota hazard and
251 immune effectiveness against pathogens (Figure 4, line types, text) for different costs of immunity
252 (purple colours indicate higher costs). If mortality caused by pathogenic microbiota is low, and/or
253 immune effectiveness is high, the optimal strategy is no immune vigilance (Figure 4, dashed line
254 peaks to the right) and is not much modulated by competition (compare left and right panels). For
255 intermediate pathogenic microbiota mortality / immune effectiveness, the optimal strategy is
256 complete vigilance in the absence of competition (Figure 4, left, dotted line peaks to the left). The
257 presence of competition between the commensal and pathogenic microbiota increases host
258 survival across the range of immune vigilance, and slightly reduces the optimal immune vigilance
259 (Figure 4, right, dotted lines increase with the dashed lines then decline at an intermediate
260 threshold). For large pathogen mortality / low immune effectiveness, in the absence of
261 competition, there is little difference in survival across a range of immune thresholds: complete
262 vigilance results in very minor increases in survival for low costs of immunity, and vice versa
263 (Figure 4, left solid line). The presence of competition results in larger survival across the board,

264 and further, alters the optimal to being no immune vigilance, with this reflecting a considerable
265 survival advantage (Figure 4, right, solid line peaks to the right).

266

267 In results presented to this point, we have effectively assumed that the abundance of commensal
268 and pathogenic microbiota are equal. In reality, pathogenic species are likely to be considerably
269 more rare. Altering results to encompass lower abundance in the pathogenic microbiota
270 community (equivalent to reducing the height of the red distribution on Figure 1) results in a
271 qualitatively similar results, but with loss of immune vigilance achieved at lower levels for
272 comparable parameter sets.

273

274 *Dysbiosis at high or low diversity*

275 In many settings, reduced microbiome diversity has been linked to ‘dysbiosis’, or reduced health
276 as a result of perturbed microbiome ecology. However, in others, such as the vaginal
277 microbiome, evidence suggests that reduced diversity is in fact a sign of health. To better capture
278 how the impacts of microbiome diversity shape selection on immune system response, we
279 assume that the range of diversity left intact in the wake of immune activity (e.g., values to the left
280 of the threshold for the immune response, Figure 1) affects the overall hazard. Diversity is
281 measured using Simpson’s diversity index,

282

$$283 D = 1 - \sum(n/N)^2,$$

284

285 where n is the number of individuals of each species (identified as positions along the x axis on
286 Figure 1) and N is the total number of individuals, in both cases taking only points below the
287 threshold. This index thus represents the probability that two individuals randomly selected from a
288 sample will belong to different species, and is thus essentially a saturating function of the position
289 of the threshold from left to right, saturating at 1.

290

291 The effect of diversity on the hazard $\mu_{m.div}$ may be either negative or positive, and thus may
292 increase or decrease the mortality hazard. The expression for the mortality hazard becomes:

293

$$294 \mu = \mu_b + A\mu_d + B\mu_d c + C\mu_d r_p + D\mu_d r_p c + \mu_m E + \mu_m F r_m + (C + D + F)I + \mu_{m.div} [1 - \sum(n/N)^2] \quad [4]$$

295

296 Conceptually, this corresponds to adding one more curve to the schematic of hazards in Figure 2,
297 either increasing (where the hazard increases with diversity) or decreasing (where the hazard
298 decreases with diversity). This illustrates that where dysbiosis increases as diversity declines
299 (e.g., as in (Lawley et al. 2012)), this will select for a decline in immune vigilance; and vice versa.

300

301 Again, as discussed in introducing the framework (Figure 1), this neglects the important fact that
302 some species may be far more important than others in terms of their effects on the host; and as
303 in the previous case, how diversity shapes the optimal immune discrimination might be
304 substantially altered by this.

305

306

307

308 Discussion

309 We provide a first framing of how the presence of microbiome species might modulate the
310 evolution of innate immunity where the immune system faces the challenge of discriminating
311 between pathogenic and other microbe species (Figure 1). We separate out direct positive effects
312 of the microbiome on reducing mortality (even in the absence of infection) with indirect effects
313 from competing with and reducing mortality effects of pathogenic species (captured by the
314 parameter c). We show that either effect can shift the evolution of host immunity towards loss of
315 vigilance; that the effects are amplified as similarity between the microbiome and pathogen
316 communities increases (Figure 3B, x axis); and that when immune effectiveness against the
317 pathogen is weak (Figure 3B, right panel) immunity can be lost even when not very costly. The
318 likelihood of loss of immune vigilance will be further amplified if dysbiosis declines with diversity.

319
320 Our framework makes explicit some of the core trade-offs which define whether microbiome
321 species presence can drive loss of immune vigilance. A comparative framing provides one
322 possible approach to testing the resulting predictions. Evidence for protective effects of the
323 microbiome exists across a range of hosts, including against *Pseudomonas syringae* in horse
324 chestnut trees (Koskella et al. 2017), tomato (Berg and Koskella 2018) and arabidopsis plants
325 (Innerebner, Knief, and Vorholt 2011); against both salmonella (Kubinak et al. 2015) and
326 intestinal infection with *Entamoeba histolytica* (Watanabe et al. 2017) in mice; and against the
327 conjunctival bacterial pathogen *Mycoplasma gallisepticum* in house finches (Thomason et al.
328 2017). Furthermore, the role of individual defensive symbionts on host fitness has been
329 demonstrated both empirically (Vorburger and Perlman 2018) and theoretically (King and Bonsall
330 2017). Our framework predicts that, all else equal, the relevant host species (or genotype) will
331 have diminished immune discrimination against pathogens that most resemble protective
332 bacteria, for example reduced responsiveness of pattern recognition receptors (Jones and Dangl
333 2006; Trdá et al. 2014).

334
335 Although we discuss our results in microbiome community terms, where all commensal and
336 pathogenic microbiota have the same (positive or negative) effect on the host, our broad
337 conclusions will hold for a single pathogenic species, with some small distribution along the
338 possible immune trigger, or a single commensal species, likewise. The tension between paying
339 the costs of immunity and those of harbouring pathogenic microbiota will play out even if the non-
340 pathogenic microbiota considered are neutral (Figure 3). For tractability, our framing also
341 collapses the possible triggers for immunity to a single axis (Figure 1). The molecular patterns
342 recognized by immunity's Pattern Recognition Receptors are by definition constrained, so varied
343 receptor responsiveness (Hawn et al. 2007; Cecil et al. 2016; Trdá et al. 2014; Vetter et al. 2012)
344 might be low dimensional. Functional characteristics indicative of pathogen's presence (e.g.,
345 deviations from homeostasis) are likely to be similar across a broad array of pathogens
346 (DeYoung and Innes 2006; Chovatiya and Medzhitov 2014), also suggesting low dimensionality.
347 Both these aspects suggest that although a single dimension may not perfectly reflect how
348 microbial species trigger immunity, it provides a reasonable starting point; albeit one perhaps
349 most relevant considering interactions happening within kingdoms (bacterial pathogens with
350 bacterial microbiome, viral pathogens with virome, and fungal pathogens with mycobiome), given
351 higher potential for overlap of shared immune mechanisms).

352
353 Our primary focus here is on innate immunity, but the front line of defense in many organisms, for
354 many species, is adaptive immunity, especially in protecting hosts from re-exposure to parasites.
355 Nevertheless, cross-talk with innate immunity remains a crucial element in the activation of
356 adaptive immunity (Iwasaki and Medzhitov 2015), so the trade-offs introduced here are likely to
357 still be relevant. Furthermore, this framing raises interesting questions about how the challenge of
358 distinguishing pathogenic from neutral or commensal microbes intersects with the intricate
359 evolution of tolerance of microbiome species displayed by adaptive immunity in vertebrates
360 (Cebula et al. 2013). On the time-scales of host ontogeny, introduction of commensal species
361 outside of a critical window of exposure could lead to a host either excluding a potentially
362 protective microbiome species, or mounting an immune defense against non-pathogenic bacteria
363 in a way that leads to autoimmunity (Gensollen et al. 2016).

364
365 Across the field, a focus on host evolution relative to pathogen (or microbiome) characteristics
366 remains relatively rare, as the shorter time-scales of microbe generations suggest much more
367 rapid selection. Nevertheless, hosts indubitably do respond to pathogen selection, and by
368 focusing on highly conserved aspects of microbe molecular make-up, we narrow the time-scale
369 mismatch in this co-evolutionary process. Yet, while our focus is on host evolution, we can also
370 evaluate our results in the context of microbe evolution. In particular, the situation of completely
371 overlapping pathogen and microbiome species distributions (equation [3]) captures the situation
372 where the pathogen has evolved to be completely indistinguishable from the microbiome. Another
373 potential direction for coevolution is selection for signaling by commensal microbiota to facilitate
374 recognition by adaptive immunity (Ost and Round 2018), equivalent to increasing the separation
375 between the two distributions in Figure 1. Both microbiome and pathogen species might also be
376 able to evolve to evade immune detection altogether. Modifying our model to include a lower
377 bound on where the immune threshold can be drawn (e.g., in Figure 1, the vertical purple line can
378 no longer go all the way to the right) will account for this by bounding the optimal strategy that the
379 host can evolve - qualitative predictions of our model are unchanged.

380
381 Longevity or ‘pace of life’ is often a focal explanatory variable when evaluating the evolution of
382 immunity (Martin, Weil, and Nelson 2007). Here, if the abundance of commensal and pathogenic
383 microbiota is constant across the life-cycle, then we expect no changes in strategy with longevity,
384 since all extra hazards are essentially an extra extrinsic mortality hazard (Caswell 2007).
385 However, in reality, rare microbiota may be less likely to colonize hosts, resulting in a later age of
386 their acquisition. Thus, if pathogenic microbiota are rare, they are likely to be acquired after
387 commensal or neutral microbiota. Given the potential for competition from already-present
388 commensal or neutral microbiota, and the ubiquitous effect of declining selection pressures with
389 age (Hamilton 1966), this could amplify selection for loss of immune vigilance. Yet, longevity is
390 likely to intersect with many other aspects of microbe ecology. In particular, longer lived species
391 might encounter a higher diversity of microbes, simply given longer exposure times during which
392 microbe colonization can occur. Where most microbial species have neutral effects, longer lived
393 species are predicted to retain immune vigilance, all else being equal, since the cumulative costs
394 of pathogens (even if rare) will translate into a significant reduction in long-lived host reproductive
395 value relative to shorter lived species. An increase of dysbiosis with microbe diversity will tend to

396 amplify this effect (noting, however, that the reverse pattern is often reported). Since many
397 features, including costs of immunity might also covary with longevity, careful titration of selection
398 pressures will be required to evaluate the strength of this prediction in natural systems.

399

400 Since protective effects of microbiome species are predicted to drive the loss of host immune
401 vigilance, hosts could be left vulnerable to attack by novel pathogens that too closely resemble
402 allies that the host has been selected to ignore. Conversely, if the presence of protective bacteria
403 actually covaries with the presence of pathogens, it has recently been shown that this can result
404 in increased host investment in resistance occurring in tandem with the presence of protective
405 symbionts (Hrček et al. 2018), again emphasizing that the details of microbial ecology matter.

406

407 To conclude, while our framework makes a number of simplifying assumptions (e.g., ignoring
408 immune responses triggered by tissue-specific damage, a widely observed phenomenon; and
409 collapsing of potentially multidimensional immune discrimination), it makes a first set of
410 predictions about optimal immune discrimination, both as a function of overlap between pathogen
411 and microbiome, and of microbiome-mediated protection. This initial framing lays a foundation for
412 future work exploring the under-studied question of selection on host immunity in light of our
413 expanding understanding of the microbiome. It also brings to light the need for more explicit data
414 examining the overlap in host recognition of pathogens and commensal microbiota.

415


416 **Author Contributions:** CJEM and BK developed the concept; CJEM developed the models;
417 CJEM and BK wrote the paper.

418

419


420

421 **Figure 1: Schematic of overlap between commensal microbiota (left, blue) and pathogenic**
422 **microbiota (right, red) communities** along a continuous axis (x axis) reflecting intensity of
423 some immune trigger (e.g., CpG ratio for TLR9). The y axis captures the abundance of
424 individuals corresponding to each point along this continuous axis. The purple line shows the
425 threshold above which an immune response is triggered, and is shaded yellow. Areas of the
426 commensal microbiota distribution above the purple line are 'false positives' (inappropriately
427 targeted by the immune system, area defined by F); areas of the pathogen distribution below the
428 purple line are 'false negatives' (inappropriately ignored by the immune system, areas defined by
429 A and B). Because both the presence or absence of the immune response, but also the presence
430 or absence of the commensal microbiota (via competition) define how pathogenic microbiota
431 affect the host, there are four different categories (A-D, see labels) associated with the pathogen
432 distribution. There are only two associated with the commensal microbiota (E and F), since we
433 are assuming no effect of the pathogen on these species. The optimization problem faced by host
434 immunity is where to draw the immune threshold (purple line) to balance the costs of the
435 pathogenic microbiota and immunity, and the benefits of the commensal microbiota. In this
436 depiction, commensal and pathogenic microbiota communities are shown as having equal
437 abundance, but in reality the pathogenic microbiota might be much rarer, and thus the height of
438 the distribution lower.
439



440


441 **Figure 2: Schematic relationship between immunity and fitness**, as a function of the position
 442 of the immune threshold (x axis), where a threshold on the far left reflects *total vigilance* (points
 443 all along the axis trigger a response), and to the far right reflect *no vigilance* (no points along the
 444 x axis trigger a response). Contributions to the hazard (y axis, top panel) from pathogenic
 445 microbiota (red) increase as immune vigilance declines; immune costs (purple) decrease as
 446 immune vigilance declines; and hazards associated with loss of a beneficial microbiota (blue line)
 447 decrease as immune vigilance declines. Each of these hazards reduces overall survival additively
 448 (y axis, middle panel); and fitness peaks when the sum the various contributions to the hazards is
 449 the smallest (dashed vertical line). Increases in pathogenic microbiota related hazards (i.e.,
 450 vertical red bars falling lower) will shift the immune threshold left (red arrow, bottom panel),
 451 increasing the optimal vigilance. Conversely, increases in the costs of immunity, or loss of
 452 impacts of a beneficial microbiota will shift the threshold to the right, thus decreasing optimal
 453 vigilance (purple and blue arrows, respectively). Competition (parameter c) and immune effects
 454 (r_p and r_m) are not illustrated here because their effect may be context specific (Figure 3).
 455



456
 457


458 **Figure 3: Cost of immunity required to drive evolution of loss of discrimination A)** This cost
 459 is the value of I (purple box) required to tip the quantities on the right of the scales (i.e., the

460 components of the hazard that decline as the immune threshold moves right and immune
 461 vigilance falls), below the quantities on the left (i.e., components that increase in value as the
 462 immune threshold moves right). The effect of overlap between commensal and pathogenic
 463 microbiota communities, governed by the competition parameter, c , contributes to both sides of
 464 the scale (red boxes). B) As the overlap between commensal and pathogenic microbiota
 465 communities increases (x axis shows proportion overlap between the two distributions), the cost
 466 of immunity required to drive evolution to no immune vigilance (y axis) decreases. All else equal,
 467 the cost is greatest for large pathogen hazards (darker red colours) in the absence of commensal
 468 microbiota (solid line corresponding to $\mu_m = -0.2$; with $\mu_m = 0$ for the dashed line; other
 469 parameters are $r_m = 0.3, c = 0.5$). Reducing the effectiveness of immunity in reducing the hazard
 470 associated with pathogen microbiota (by moving from $r_p = 0.1$ left panel, to $r_p = 0.7$ right panel,
 471 corresponding to ineffectual immunity) results in lower costs allowing loss of host immunity (far
 472 right). If the pathogenic microbiota community is rarer than the commensal microbiota community
 473 (corresponding to a reduction in the height of the pathogen distribution in Figure 1) this further
 474 reduces the cost of immunity required to drive loss of immune vigilance.
 475



476

477
 478 **Figure 4: Effect of competition on survival** (y axis) across a range of levels of immune
 479 vigilance (x axis) in the absence (left, $c = 1$) and presence (right, $c = 0$) of competition for
 480 different combinations (text, line types) of the product of pathogen mortality ($\mu_d = 0.01$ or $\mu_d = 3$)
 481 and immune effectiveness ($r_p = 0.01$ or $r_p = 1$) for different costs of immunity ($I = 0.1$ shown in
 482 light blue is the lowest cost; through to $I = 0.2$, in purple as the highest cost, i.e., corresponding to
 483 the greatest reduction in survival). The presence of competition increases survival (right hand plot
 484 vs. left), but also can qualitatively change the outcome of selection on immune vigilance. For
 485 large pathogen microbiota associated mortality and/or low immune effectiveness (solid line) the
 486 outcome switches from close to no directional selection on vigilance to strong selection for no
 487 vigilance (solid lines, compare left and right), while for intermediate pathogen mortality and/or
 488 immune effectiveness, selection shifts from favouring complete vigilance to intermediate vigilance
 489 (dotted line, compare left and right).
 490



491
 492
 493

494 References

- 495 Berg, Maureen, and Britt Koskella. 2018. "Nutrient- and Dose-Dependent Microbiome-Mediated
496 Protection against a Plant Pathogen." *Current Biology: CB* 28 (15): 2487–92.e3.
- 497 Caswell, Hal. 2007. "Extrinsic Mortality and the Evolution of Senescence." *Trends in Ecology &*
498 *Evolution* 22 (4): 173–74.
- 499 Cebula, Anna, Michal Seweryn, Grzegorz A. Rempala, Simarjot Singh Pabla, Richard A.
500 McIndoe, Timothy L. Denning, Lynn Bry, Piotr Kraj, Pawel Kisielow, and Leszek Ignatowicz.
501 2013. "Thymus-Derived Regulatory T Cells Contribute to Tolerance to Commensal
502 Microbiota." *Nature* 497 (7448): 258–62.
- 503 Cecil, Jessica D., Neil M. O'Brien-Simpson, Jason C. Lenzo, James A. Holden, Yu-Yen Chen,
504 William Singleton, Katelyn T. Gause, Yan Yan, Frank Caruso, and Eric C. Reynolds. 2016.
505 "Differential Responses of Pattern Recognition Receptors to Outer Membrane Vesicles of
506 Three Periodontal Pathogens." *PloS One* 11 (4): e0151967.
- 507 Chovatiya, Raj, and Ruslan Medzhitov. 2014. "Stress, Inflammation, and Defense of
508 Homeostasis." *Molecular Cell*. 54(2): 281-288.
- 509 DeYoung, Brody J., and Roger W. Innes. 2006. "Plant NBS-LRR Proteins in Pathogen Sensing
510 and Host Defense." *Nature Immunology* 7 (12): 1243–49.
- 511 Felix, Georg, Juliana D. Duran, Sigrid Volko, and Thomas Boller. 1999. "Plants Have a Sensitive
512 Perception System for the Most Conserved Domain of Bacterial Flagellin." *The Plant Journal:*
513 *For Cell and Molecular Biology* 18 (3): 265–76.
- 514 Friesen, Maren L., Stephanie S. Porter, Scott C. Stark, Eric J. von Wettberg, Joel L. Sachs, and
515 Esperanza Martinez-Romero. 2011. "Microbially Mediated Plant Functional Traits." *Annual*
516 *Review of Ecology, Evolution, and Systematics* 42 (1): 23–46.
- 517 Gensollen, Thomas, Shankar S. Iyer, Dennis L. Kasper, and Richard S. Blumberg. 2016. "How
518 Colonization by Microbiota in Early Life Shapes the Immune System." *Science* 352 (6285):
519 539–44.
- 520 Gómez-Gómez, Lourdes, and Thomas Boller. 2002. "Flagellin Perception: A Paradigm for Innate
521 Immunity." *Trends in Plant Science* 7 (6): 251–56.
- 522 Hamilton, W. D. 1966. "The Moulding of Senescence by Natural Selection." *Journal of Theoretical*
523 *Biology*. [https://doi.org/10.1016/0022-5193\(66\)90184-6](https://doi.org/10.1016/0022-5193(66)90184-6).
- 524 Hanssen, S. A., D. Hasselquist, I. Folstad, and K. E. Erikstad. 2004. "Costs of Immunity: Immune
525 Responsiveness Reduces Survival in a Vertebrate." *Proceedings of the Royal Society B:*
526 *Biological Sciences* 271 (1542): 925–30.
- 527 Hawn, Thomas R., E. Ann Misch, Sarah J. Dunstan, Guy E. Thwaites, Nguyen T. N. Lan, Hoang
528 T. Quy, Tran T. H. Chau, et al. 2007. "A Common Human TLR1 Polymorphism Regulates the
529 Innate Immune Response to Lipopeptides." *European Journal of Immunology* 37 (8): 2280–
530 89.
- 531 Hrček, Jan, Benjamin J. Parker, Ailsa H. C. McLean, Jean-Christophe Simon, Ciara M. Mann,
532 and H. Charles J. Godfray. 2018. "Hosts Do Not Simply Outsource Pathogen Resistance to
533 Protective Symbionts." *Evolution*. 72(7): 1488-1499.
- 534 Innerebner, Gerd, Claudia Knief, and Julia A. Vorholt. 2011. "Protection of Arabidopsis Thaliana
535 against Leaf-Pathogenic Pseudomonas Syringae by Sphingomonas Strains in a Controlled
536 Model System." *Applied and Environmental Microbiology* 77 (10): 3202–10.
- 537 Iwasaki, Akiko, and Ruslan Medzhitov. 2015. "Control of Adaptive Immunity by the Innate
538 Immune System." *Nature Immunology* 16(4): 34.
- 539 Jaenike, John. 2012. "Population Genetics of Beneficial Heritable Symbionts." *Trends in Ecology*
540 *& Evolution* 27 (4): 226–32.
- 541 Jones, Jonathan D. G., and Jeffery L. Dangl. 2006. "The Plant Immune System." *Nature*
542 444(7117): 323.
- 543 King, Kayla C., and Michael B. Bonsall. 2017. "The Evolutionary and Coevolutionary

- 544 Consequences of Defensive Microbes for Host-Parasite Interactions.” *BMC Evolutionary*
545 *Biology* 17 (1): 190.
- 546 Koskella, Britt, Lindsay J. Hall, and C. Jessica E. Metcalf. 2017. “The Microbiome beyond the
547 Horizon of Ecological and Evolutionary Theory.” *Nature Ecology & Evolution* 1 (11): 1606–
548 15.
- 549 Koskella, Britt, Sean Meaden, William J. Crowther, Roosa Leimu, and C. Jessica E. Metcalf.
550 2017. “A Signature of Tree Health? Shifts in the Microbiome and the Ecological Drivers of
551 Horse Chestnut Bleeding Canker Disease.” *The New Phytologist* 215 (2): 737–46.
- 552 Kubinak, Jason L., W. Zac Stephens, Ray Soto, Charisse Petersen, Tyson Chiaro, Lasha
553 Gogokhia, Rickesha Bell et al. 2015. “MHC variation sculpts individualized microbial
554 communities that control susceptibility to enteric infection.” *Nature communications* 6: 8642.
- 555 Lawley, Trevor D., Simon Clare, Alan W. Walker, Mark D. Stares, Thomas R. Connor, Claire
556 Raisen, David Goulding, et al. 2012. “Targeted Restoration of the Intestinal Microbiota with a
557 Simple, Defined Bacteriotherapy Resolves Relapsing *Clostridium Difficile* Disease in Mice.”
558 *PLoS Pathogens* 8 (10): e1002995.
- 559 Leung, Chung-Yin, and Joshua S. Weitz. 2019. “Not by (Good) Microbes Alone: Towards
560 Immunocommenseal Therapies.” *Trends in Microbiology* 27 (4): 294–302.
- 561 Levy, Asaf, Isai Salas Gonzalez, Maximilian Mittelvielfhaus, Scott Clingenpeel, Sur Herrera
562 Paredes, Jiamin Miao, Kunru Wang, et al. 2018. “Genomic Features of Bacterial Adaptation
563 to Plants.” *Nature Genetics* 50 (1): 138–50.
- 564 Littman, Dan R., and Eric G. Pamer. 2011. “Role of the Commensal Microbiota in Normal and
565 Pathogenic Host Immune Responses.” *Cell Host & Microbe* 10 (4): 311–23.
- 566 Martin, Lynn B., 2nd, Zachary M. Weil, and Randy J. Nelson. 2007. “Immune Defense and
567 Reproductive Pace of Life in *Peromyscus* Mice.” *Ecology* 88 (10): 2516–28.
- 568 Ost, Kyla S., and June L. Round. 2018. “Communication Between the Microbiota and Mammalian
569 Immunity.” *Annual Review of Microbiology* 72 (September): 399–422.
- 570 Pohar, Jelka, Duško Lainšček, Ryutarō Fukui, Chikako Yamamoto, Kensuke Miyake, Roman
571 Jerala, and Mojca Benčina. 2015. “Species-Specific Minimal Sequence Motif for
572 Oligodeoxyribonucleotides Activating Mouse TLR9.” *Journal of Immunology* 195 (9): 4396–
573 4405.
- 574 Sheldon, B. C., and S. Verhulst. 1996. “Ecological Immunology: Costly Parasite Defences and
575 Trade-Offs in Evolutionary Ecology.” *Trends in Ecology & Evolution* 11 (8): 317–21.
- 576 Snelders, Nick C., Graeme J. Kettles, Jason J. Rudd, and Bart P. H. J. Thomma. 2018. “Plant
577 Pathogen Effector Proteins as Manipulators of Host Microbiomes?” *Molecular Plant*
578 *Pathology* 19 (2): 257–59.
- 579 Thaiss, Christoph A., Niv Zmora, Maayan Levy, and Eran Elinav. 2016. “The Microbiome and
580 Innate Immunity.” *Nature*. 535(7610): 65.
- 581 Thomason, Courtney A., Nathan Mullen, Lisa K. Belden, Meghan May, and Dana M. Hawley.
582 2017. “Resident Microbiome Disruption with Antibiotics Enhances Virulence of a Colonizing
583 Pathogen.” *Scientific Reports* 7 (1): 16177.
- 584 Trdá, Lucie, Olivier Fernandez, Freddy Boutrot, Marie-Claire Héloir, Jani Kelloniemi, Xavier Daire,
585 Marielle Adrian, et al. 2014. “The Grapevine Flagellin Receptor VvFLS2 Differentially
586 Recognizes Flagellin-Derived Epitopes from the Endophytic Growth-Promoting Bacterium
587 *Burkholderia Phytofirmans* and Plant Pathogenic Bacteria.” *The New Phytologist* 201 (4):
588 1371–84.
- 589 Vetter, M. Madlen, Ilkka Kronholm, Fei He, Heidrun Häweker, Matthieu Reymond, Joy Bergelson,
590 Silke Robatzek, and Juliette de Meaux. 2012. “Flagellin Perception Varies Quantitatively in
591 *Arabidopsis thaliana* and Its Relatives.” *Molecular Biology and Evolution* 29 (6): 1655–67.
- 592 Vogel, Christine, Natacha Bodenhausen, Wilhelm Grisse, and Julia A. Vorholt. 2016. “The
593 *Arabidopsis* Leaf Transcriptome Reveals Distinct but Also Overlapping Responses to
594 Colonization by Phyllosphere Commensals and Pathogen Infection with Impact on Plant

595 Health." *The New Phytologist* 212 (1): 192–207.
596 Vorburger, Christoph, and Steve J. Perlman. 2018. "The role of defensive symbionts in host–
597 parasite coevolution." *Biological Reviews* 93(4): 1747-1764.
598 Watanabe, Koji, Carol A. Gilchrist, Md Jashim Uddin, Stacey L. Burgess, Mayuresh M.
599 Abhyankar, Shannon N. Moonah, Zannatun Noor, et al. 2017. "Microbiome-Mediated
600 Neutrophil Recruitment via CXCR2 and Protection from Amebic Colitis." *PLoS Pathogens* 13
601 (8): e1006513.

602

603

604

605